| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Liquidia Corp | Director | Common Stock | 40,755 | $611,325 | $15.00 | 17 Jun 2025 | Direct |
| Liquidia Corp | Director | Common Stock | 30,000 | $450,000 | $15.00 | 17 Jun 2025 | Through Revocable Trust of Arthur S. Kirsch |
| Atea Pharmaceuticals, Inc. | Director | Common Stock | 35,710 | $109,273 | $3.06 | 20 Feb 2025 | Direct |
| Atea Pharmaceuticals, Inc. | Director | Common Stock | 10,000 | $30,600 | $3.06 | 20 Feb 2025 | By trust |
| Atea Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 164,800 | 20 Feb 2025 | Direct | ||
| Evommune, Inc. | Director | Stock Option (Right to Buy) | 37,960 | 05 Nov 2025 | Direct | ||
| Kadmon Holdings, Inc. | Director | Common Stock | 0 | $9.50 | 09 Nov 2021 | Direct | |
| Kadmon Holdings, Inc. | Director | Stock Option (right to buy) | 0 | $5.54 | 09 Nov 2021 | Direct |